Meet Dr. Sharon Yavrom: Imugene’s (ASX:IMU) new Executive Director, Clinical Scientist

July 04, 2022 12:13 PM AEST | By Manisha

Meet Dr. Sharon Yavrom: Imugene’s (ASX:IMU) new Executive Director, Clinical Scientist — Image source: Company Website

About Dr. Yavrom

Dr. Sharon Yavrom is an accomplished clinical scientist, who holds about 20 years of industry experience in both emerging and established pharmaceutical companies. Previously, she has held positions at many industry-leading companies, including BMS, Amgen, and TAP Pharmaceuticals.

She has dedicated the last ten years of her career to working exclusively for start-up companies, with a focus on the oncology therapeutics space. These companies include Synta Pharmaceuticals, Tocagen, Aduro, Puma Biotechnology, MEI Pharma and Oncternal.

In terms of educational qualifications, Dr. Yavrom holds a Ph.D. degree in Pathobiology from the Keck School of Medicine of USC (University of Southern California). She also holds a Bachelor of Science (B.Sc.) degree in Biology from California-based San Jose State University.

Ideal addition to management team

Dr. Yavrom has served as the clinical study lead for multiple clinical trials. Moreover, she has immense experience with various tumour types, including NSCLC, HER2+ breast cancer, glioblastoma, colorectal cancer, non-invasive bladder cancer, Ewing’s Sarcoma, NHL and CLL.

Remarks by Imugene’s MD & CEO, Ms Leslie Chong:

Do Not Miss: What lies ahead for Imugene Limited (ASX:IMU) in 2022?

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Full Name

Mobile

By submitting your details above and clicking on the 'Download Report' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.